CAMBRIDGE, Mass., Oct. 31 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that the trading symbol for its Class A common stock will revert from BPURD to BPUR at the open of the market on Wednesday, October 31, 2007. Outstanding warrants that trade on the OTCBB will revert to the following ticker symbols: BPREW reverting to BPURW; BPREZ reverting to BPURZ; and BPREL reverting to BPURL.
Biopure Corporation
Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. Biopure has applied in the United Kingdom for regulatory approval of a proposed orthopedic surgical anemia indication. The company is developing Hemopure for several other indications and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 bovine)], or HBOC-301, the only oxygen therapeutic approved by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 186,000 units of Oxyglobin, which have been used to treat an estimated 100,000 animals.
Statements in this release that are not strictly historical are
forward- looking statements, including those statements implying that any
planned clinical trial will be carried out or that study results will be as
desired, statements related to the timing and response of the M
'/>"/>
| SOURCE Biopure Corporation Copyright©2007 PR Newswire. All rights reserved |